Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimagedine SCHEMBL1551679 | 0.83 | CYP2D6 (0.55) | CYP2D6MAPK1SNCAPRSS1F2 | |
| Biguanide SCHEMBL27660583 | 0.83 | CYP2D6 (0.55) | CYP2D6MAPK1SNCAPRSS1F2 | |
| Hydroxyguanidine SCHEMBL13673553 | 0.83 | CYP2D6 (0.55) | CYP2D6MAPK1SNCAPRSS1F2 | |
| Guanidine SCHEMBL811270 | 0.82 | CYP2D6 (0.61) | CYP2D6MAPK1SNCAPRSS1F2 | |
| SCHEMBL3884567 | 0.80 | CYP2D6 (0.55) | CYP2D6MAPK1SNCAPRSS1F2 | |
| SCHEMBL2259114 | 0.79 | SNCA (0.49) | CYP2D6MAPK1SNCACYP1A2CYP3A4 | |
| Thiourea SCHEMBL1577311 | 0.79 | CYP2D6 (0.58) | CYP2D6MAPK1SNCAPRSS1F2 | |
| Isopropylamine SCHEMBL2350740 | 0.79 | CYP2D6 (0.53) | CYP2D6MAPK1SNCAPRSS1F2 | |
| Isobutyramide SCHEMBL6491554 | 0.78 | CYP2D6 (0.53) | CYP2D6MAPK1SNCAPRSS1F2 | |
| SCHEMBL1274859 | 0.77 | CYP2D6 (0.51) | CYP2D6MAPK1SNCAPRSS1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | disclosed |
| EP-1194430-A1 | NOVEL PROCESS | NOVO NORDISK A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002410-A1 | NOVEL PROCESS | NOVO NORDISK A/S (DK) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119969-A1 | Novel process | CYP3A5, CYP4F2, CYP4F12 | CYP2D6 20/4885MAPK1 2799/4885SNCA 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.